Breaking Cancer’s Shield: Reversing Opioid-Mediated Immunotherapy Inefficiency via TLR4–PD-L1 Inhibitors

Overview

Cancer pain affects 66% of patients during treatment and up to 90% with advanced disease (van den Beuken-van Everdingen et al., 2016), making morphine essential in treatment. However, clinical studies illustrate that higher morphine requirements negatively correlate with survival outcomes in non-small cell lung cancer patients (Maher et al., 2014; Zylla et al., 2014), potentially mediated by accumulation of morphine-3-glucuronide (M3G), a morphine metabolite. M3G activates Toll-like receptor 4 (TLR4) on cancer cells, up-regulating PD-L1 (Wang et al., 2021), an immune checkpoint protein that suppresses T lymphocyte activity. This study develops a streamlined in silico-in vitro pipeline to identify FDA-approved drugs that can block M3G-induced PD-L1 up-regulation. Molecular docking analysis of the TLR4/MD-2 complex identifies Conivaptan (vasopressin V1a/V2 receptor antagonist) as a candidate inhibitor. A549 lung adenocarcinoma and A431 epidermoid carcinoma cells are treated with M3G (5-10 µM), TAK-242 (1 µM), and Conivaptan (10 µM) and PD-L1 mRNA expression is quantified using RT-qPCR normalized to three housekeeping genes (GAPDH, HPRT, PPIA). In A549 cells, M3G (10 µM) induced a ~2.01-fold increase in PD-L1 expression relative to the methanol vehicle control. Co-treatment with conivaptan reduced PD-L1 expression by ~23% (1.54-fold vs. 2.01-fold). These findings highlight the potential for pharmacological modulation of opioid-associated immune signaling in cancer cells and underscore the importance of cancer specific patient care. Collectively, this work provides preliminary evidence that repurposed therapeutics can influence opioid-associated PD-L1 regulation, supporting further investigation into strategies that could mitigate immune suppression in cancer patients receiving opioid analgesia.